Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)

  1. Drake, M.J.
  2. Chapple, C.
  3. Esen, A.A.
  4. Athanasiou, S.
  5. Cambronero, J.
  6. Mitcheson, D.
  7. Herschorn, S.
  8. Saleem, T.
  9. Huang, M.
  10. Siddiqui, E.
  11. Stölzel, M.
  12. Herholdt, C.
  13. MacDiarmid, S.
Revista:
European Urology

ISSN: 1873-7560,  0302-2838

Any de publicació: 2016

Volum: 70

Número: 1

Pàgines: 136-145

Tipus: Article

DOI: 10.1016/J.EURURO.2016.02.030 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus